Article Text
Abstract
Spasticity is common in many neurological disorders, such as stroke and multiple sclerosis. It is part of the upper motor neurone syndrome manifesting as increased tone, clonus, spasms, spastic dystonia and co-contractions. The impact of spasticity varies from it being a subtle neurological sign to severe spasticity causing pain and contractures. Existing spasticity can be worsened by external factors such as constipation, urinary tract infections or pressure ulcers. Its management involves identification and elimination of triggers; neurophysiotherapy; oral medications such as baclofen, tizanidine and dantrolene; focal injection of botulinum toxin, alcohol or phenol, or baclofen delivered intrathecally through a pump; and surgical resection of selected dorsal roots of the spinal cord. This article reviews the current understanding of pathophysiology, clinical features and management of spasticity.
Statistics from Altmetric.com
Linked Articles
- Editors' choice
Read the full text or download the PDF:
Other content recommended for you
- The management of spasticity in adults
- Comparing the effects of two spasticity management strategies on the long-term outcomes of individuals with bilateral spastic cerebral palsy: a multicentre cohort study protocol
- An overview of drug therapies used in the treatment of dystonia and spasticity in children
- The need for and provision of intrathecal baclofen therapy for the management of spasticity in England: an assessment of the Hospital Episode Statistics database
- Intrathecal baclofen pumps: what the neurologist needs to know
- Neurosurgical management of elevated tone in childhood: interventions, indications and uncertainties
- Spasticity in children and young people with non-progressive brain disorders: summary of NICE guidance
- Managing common symptoms of cerebral palsy in children
- The management of spasticity
- Intrathecal baclofen pumps in the management of hypertonia in childhood: a UK and Ireland wide survey